P P+Cis P+Cb Median age (range) (years) 63.0 (31, 85) 59.5 (26, 77) 61.0 (25, 80) Male (%) 75.9 75.6 81.3 Karnofsky performance status ≥ 80, % of pts* 74.5 81.8 81.7 RR, % of pts (95% CI) 12.1 (9.1,15.7) 23.8 (17.3, 31.4) 16.8 (12.7, 21.7) Disease control rate (responders +SD), % of pts, (95% CI) 58.1 (53.0, 63.0) 67.5 (59.5, 74.9) 66.3 (60.5, 71.8)
Conclusions:
Changes in patient-reported LCSS-Meso items correlate with radiological response to therapy. PROs appear to be at least as sensitive in predicting response to therapy as objective measures such as FVC. The LCSS-Meso may serve as an effective, inexpensive, and easy-to-administer alternative to radiological assessment for monitoring response to therapy for MPM. Prospective studies are needed to confirm these findings.
C5-05
Mesothelioma, Wed, 10:30 -12:15
The yield of EUS-FNA in early stage malignant pleural mesothelioma Tournoy, Kurt 1 Burgers, Jacobus A. 2 Meerbeeck, Jan v. 1 Baas, Paul 2 1 University Hospital, Ghent, Belgium 2 Netherlands Cancer Institute, Amsterdam, The Netherlands Background: Selected patients with limited (cT1-3N0) malignant pleural mesothelioma are being considered for a multimodality therapy with induction chemotherapy followed by extrapleural resection and radiotherapy. Since invasion of the mediastinal lymph nodes is a negative prognostic factor, cervical mediastinoscopy is recommended for staging in these patients. Transoesophageal Endoscopic Ultrasound with a linear scanning ultrasound endoscope and real time guided fine needle aspiration (EUS-FNA) enables mediastinal lymph node staging with high accuracy in lung cancer patients.
